Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Eli Lilly and Company v. Eagle Pharmaceuticals, Inc.
Case Number:
1:17-cv-01293
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
December 17, 2019
Eagle, Eli Lilly Drop Dueling Cancer Drug Patent Claims
Eagle Pharmaceuticals has agreed to drop its lingering antitrust claims over Eli Lilly's chemotherapy drug Alimta after the companies reached a settlement ending patent litigation and allowing Eagle to launch a branded alternative in 2022.
-
November 28, 2018
Eli Lilly Wins Stay In Eagle Antitrust Suit Amid Patent Fight
A Delaware federal court has granted Eli Lilly and Co.'s request to stay an antitrust suit brought by Eagle Pharmaceuticals Inc., saying that waiting until a related patent infringement case is resolved would simplify things.